Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma

Ying Li,1,* Jiani Yuan,1,* Qian Yang,1 Wei Cao,1 Xuanxuan Zhou,1 Yanhua Xie,1 Honghai Tu,2 Ya Zhang,1 Siwang Wang1 1Department of Natural Medicine and Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an, People’s Republic of China; 2Instit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li Y, Yuan J, Yang Q, Cao W, Zhou X, Xie Y, Tu H, Zhang Y, Wang S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0efaf599ea7d4f8a8d932f8d842a9112
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0efaf599ea7d4f8a8d932f8d842a9112
record_format	dspace
spelling	oai:doaj.org-article:0efaf599ea7d4f8a8d932f8d842a91122021-12-02T07:44:03ZImmunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma1178-2013https://doaj.org/article/0efaf599ea7d4f8a8d932f8d842a91122014-12-01T00:00:00Zhttp://www.dovepress.com/immunoliposome-co-delivery-of-bufalin-and-anti-cd40-antibody-adjuvant--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Ying Li,1,* Jiani Yuan,1,* Qian Yang,1 Wei Cao,1 Xuanxuan Zhou,1 Yanhua Xie,1 Honghai Tu,2 Ya Zhang,1 Siwang Wang1 1Department of Natural Medicine and Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an, People’s Republic of China; 2Institute for Drug and Instrument Control, Xinjiang Military Area Command, Urumqi, Xinjiang, People’s Republic of China *These authors contributed equally to this work Abstract: Liposomes constitute one of the most popular nanocarriers for improving the delivery and efficacy of agents in cancer patients. The purpose of this study was to design and evaluate immunoliposome co-delivery of bufalin and anti-CD40 to induce synergetic therapeutic efficacy while eliminating systemic side effects. Bufalin liposomes (BFL) conjugated with anti-CD40 antibody (anti-CD40-BFL) showed enhanced cytotoxicity compared with bufalin alone. In a mouse B16 melanoma model, intravenous injection of anti-CD40-BFL achieved smaller tumor volume than did treatment with BFL (average: 117 mm3 versus 270 mm3, respectively); the enhanced therapeutic efficacy through a caspase-dependent pathway induced apoptosis, which was confirmed using terminal deoxynucleotidyl transferase-mediated dUTP-Fluorescein nick end labeling and Western blot assay. Meanwhile, anti-CD40-BFL elicited unapparent body-weight changes and a significant reduction in serum levels of tumor necrosis factor-α, interleukin-1β, interleukin-6, interferon-γ, and hepatic enzyme alanine transaminase, suggesting minimized systemic side effects. This may be attributed to the mechanism by which liposomes are retained within the tumor site for an extended period of time, which is supported by the following biodistribution and flow cytometric analyses. Taken together, the results demonstrated a highly promising strategy for liposomal vehicle transport of anti-CD40 plus bufalin that can be used to enhance antitumor effects via synergetic systemic immunity while blocking systemic toxicity. Keywords: liposomes, bufalin, anti-CD40, chemoimmunotherapyLi YYuan JYang QCao WZhou XXie YTu HZhang YWang SDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 5683-5700 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Li Y Yuan J Yang Q Cao W Zhou X Xie Y Tu H Zhang Y Wang S Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
description	Ying Li,1,* Jiani Yuan,1,* Qian Yang,1 Wei Cao,1 Xuanxuan Zhou,1 Yanhua Xie,1 Honghai Tu,2 Ya Zhang,1 Siwang Wang1 1Department of Natural Medicine and Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an, People’s Republic of China; 2Institute for Drug and Instrument Control, Xinjiang Military Area Command, Urumqi, Xinjiang, People’s Republic of China *These authors contributed equally to this work Abstract: Liposomes constitute one of the most popular nanocarriers for improving the delivery and efficacy of agents in cancer patients. The purpose of this study was to design and evaluate immunoliposome co-delivery of bufalin and anti-CD40 to induce synergetic therapeutic efficacy while eliminating systemic side effects. Bufalin liposomes (BFL) conjugated with anti-CD40 antibody (anti-CD40-BFL) showed enhanced cytotoxicity compared with bufalin alone. In a mouse B16 melanoma model, intravenous injection of anti-CD40-BFL achieved smaller tumor volume than did treatment with BFL (average: 117 mm3 versus 270 mm3, respectively); the enhanced therapeutic efficacy through a caspase-dependent pathway induced apoptosis, which was confirmed using terminal deoxynucleotidyl transferase-mediated dUTP-Fluorescein nick end labeling and Western blot assay. Meanwhile, anti-CD40-BFL elicited unapparent body-weight changes and a significant reduction in serum levels of tumor necrosis factor-α, interleukin-1β, interleukin-6, interferon-γ, and hepatic enzyme alanine transaminase, suggesting minimized systemic side effects. This may be attributed to the mechanism by which liposomes are retained within the tumor site for an extended period of time, which is supported by the following biodistribution and flow cytometric analyses. Taken together, the results demonstrated a highly promising strategy for liposomal vehicle transport of anti-CD40 plus bufalin that can be used to enhance antitumor effects via synergetic systemic immunity while blocking systemic toxicity. Keywords: liposomes, bufalin, anti-CD40, chemoimmunotherapy
format	article
author	Li Y Yuan J Yang Q Cao W Zhou X Xie Y Tu H Zhang Y Wang S
author_facet	Li Y Yuan J Yang Q Cao W Zhou X Xie Y Tu H Zhang Y Wang S
author_sort	Li Y
title	Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
title_short	Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
title_full	Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
title_fullStr	Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
title_full_unstemmed	Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
title_sort	immunoliposome co-delivery of bufalin and anti-cd40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/0efaf599ea7d4f8a8d932f8d842a9112
work_keys_str_mv	AT liy immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT yuanj immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT yangq immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT caow immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT zhoux immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT xiey immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT tuh immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT zhangy immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma AT wangs immunoliposomecodeliveryofbufalinandanticd40antibodyadjuvantinducessynergetictherapeuticefficacyagainstmelanoma
_version_	1718399201375682560

Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma

Ejemplares similares